Analysis of amoxicillin and five impurities on the Agilent 1220 Infinity LC System

Similar documents
Application Note. Author. Abstract. Pharmaceuticals. Detlef Wilhelm ANATOX GmbH & Co. KG. Fuerstenwalde, Germany mau

ISET. Agilent 1290 Infinity Binary LC with ISET, emulation of the Waters Alliance 2695 LC system analyzing aromatic acids. Application Note.

Application Note. Author. Abstract. Pharmaceuticals. A.G.Huesgen Agilent Technologies, Inc. Waldbronn, Germany

Agilent 1290 Infinity Binary LC System with ISET Emulation of a Waters Alliance 2695 LC Applying Concave, Convex, and Linear Gradients

Emulation of the Agilent 1100 Series LC Through Waters Empower Software Analysis of an Analgesic Mixture

Quantification of genotoxic "Impurity D" in Atenolol by LC/ESI/MS/MS with Agilent 1200 Series RRLC and 6410B Triple Quadrupole LC/MS

Agilent 1290 Infinity Binary LC System with ISET - Emulation of the Waters Alliance 2695 LC system analyzing b-blockers

Performance characteristics of the 1260 Infinity Quaternary LC system

Automated Scouting of Stationary and Mobile Phases Using the Agilent 1290 Infinity II Method Development Solution

Agilent 1290 Infinity Quaternary LC Support of Columns with 2.1 to 4.6 mm ID to 1200 bar

Performance Characteristics of the Agilent 1220 Infinity Gradient LC system

Method Transfer from an Agilent 1200 Series LC to an Agilent 1260 Infinity II LC

Technical Overview. Author. Abstract. A.G.Huesgen Agilent Technologies, Inc. Waldbronn, Germany

Scale-up with the Agilent SD-1 Purification System analytical and preparative runs on a single system

Automated alternating column regeneration on the Agilent 1290 Infinity LC

Analytical Instrument Qualification According to USP <1058>: Requirements and Examples for the Agilent 1290 Infinity LC System

Application Note. Environmental. Agilent 1290 Infinity Binary LC. with ISET and fine-tuning. Agilent 1290 Infinity Binary LC.

High-Throughput LC/MS Purification of Pharmaceutical Impurities

Reducing Cycle Time for Charge Variant Analysis of Monoclonal Antibodies

Fast Method Development Using the Agilent 1290 Infinity Quaternary LC System with Column Selection Valve

Technical Overview. Author. Abstract. Edgar Naegele Agilent Technologies, Inc. Waldbronn, Germany

High-resolution Analysis of Charge Heterogeneity in Monoclonal Antibodies Using ph-gradient Cation Exchange Chromatography

Separate and Quantify Rituximab Aggregates and Fragments with High-Resolution SEC

Application Note. Author. Abstract. Small Molecule Pharmaceuticals & Generics. A.G.Huesgen Agilent Technologies, Inc. Waldbronn, Germany

Improved Sensitivity with the Agilent 1290 Infinity Evaporative Light Scattering Detector (ELSD)

Comparing gradient transfer of isocratic hold and delay volume addition using the Agilent 1290 Infinity LC with ISET

Seamless Method Transfer from an Agilent 1260 Infinity Bio-inert LC to an Agilent 1260 Infinity II Bio-inert LC

Analysis of Atrazine in Drinking Water at the ppb Level Using New Agilent Reversed Phase LC Columns. Application. Author. Abstract.

Application Note. Authors. Abstract. Introduction. Pharmaceutical

Disulfide Linkage Analysis of IgG1 using an Agilent 1260 Infinity Bio inert LC System with an Agilent ZORBAX RRHD Diphenyl sub 2 µm Column

Application Note. Authors. Abstract. Biopharmaceuticals

Developing Purification Strategies for the Agilent 1260 Infinity II Preparative LC/MSD System

Analysis of TCM injections using the Agilent 1290 Infinity LC system

Size Exclusion Chromatography of Biosimilar and Innovator Insulin Using the Agilent AdvanceBio SEC column

Fast and High-Resolution Reversed-Phase Separation of Synthetic Oligonucleotides

Application Note. Author. Abstract. Small Molecule Pharmaceuticals. Sonja Krieger Agilent Technologies, Inc. Waldbronn, Germany

Determination of Asarinin in Xixin (Asari Radix Et Rhizoma)

Automated QbD-Based Method Development and Validation of Oxidative Degraded Atorvastatin

Quality-by-Design-Based Method Development Using an Agilent 1290 Infinity II LC

Clone Selection Using the Agilent 1290 Infinity Online 2D-LC/MS Solution

Protein Separation with ph Gradients Using Composite Buffer Systems Calculated by the Agilent Buffer Advisor Software

Application Note. Author. Abstract. Biopharmaceuticals. Verified for Agilent 1260 Infinity II LC Bio-inert System. Sonja Schneider

Applications of 2D-LC in Pharmaceutical Analysis

10. Validated Normal Phase HPLC Method for the Determination. Fulvestrant is primarily used in the treatment of hormone receptor

Fast Analysis of Environmental Phenols with Agilent Poroshell 120 EC-C18 Columns

Agilent SD-1 Purification System. Purify your way SD-1

Reversed-phase Separation of Intact Monoclonal Antibodies Using Agilent ZORBAX Rapid Resolution High Definition 300SB-C8 1.

Analysis of Nucleosides Using an Agilent Infinity II High Speed UHPLC with the 6130 Single Quadrupole Mass Selective Detector

Application of Agilent AdvanceBio Desalting-RP Cartridges for LC/MS Analysis of mabs A One- and Two-dimensional LC/MS Study

Charge Heterogeneity Analysis of Rituximab Innovator and Biosimilar mabs

Fraction Analysis of Cysteine Linked Antibody-Drug Conjugates Using Hydrophobic Interaction. chromatography. Agilent 1260 Infinity II Bio-Inert System

Practical Applications of Method Translation Using the Agilent Method Translation Tool. eseminar and Workshop

Agilent 1290 Infinity LC with ISET under Waters Empower control Emulation of Agilent 1100 Series LC

Method Translation in Liquid Chromatography

Application Note. Biopharma. Authors. Abstract. James Martosella, Phu Duong Agilent Technologies, Inc Centreville Rd Wilmington, DE 19808

As reported before, the employed dose was 10 mg/ml is in according with commonly used dose.

Multiple Detector Approaches to Protein Aggregation by SEC

Performance characteristics of the Agilent 1100 Series capillary LC system using diode-array UV and MS for detection. Technical Note.

AdvanceBio Peptide Mapping

Method Transfer from an Agilent 1260 Infinity LC to an Agilent 1260 Infinity II LC

Benefits of 2D-LC/MS/MS in Pharmaceutical Bioanalytics

Peptide Mapping: A Quality by Design (QbD) Approach

High-throughput and Sensitive Size Exclusion Chromatography (SEC) of Biologics Using Agilent AdvanceBio SEC Columns

New Advances in UHPLC -Resolution, Speed & Sensitivity

Genotoxicity is the property of a compound

Agilent AdvanceBio SEC Columns for Aggregate Analysis: Instrument Compatibility

Technical Overview. Author. Abstract. A.G.Huesgen Agilent Technologies, Inc. Waldbronn, Germany

Separation of Recombinant Human Erythropoietin (repo) Using Agilent Bio SEC-3

ultra why micro-lc? product note introducing the ExpressLC -Ultra system: UHPLC with all the advantages of micro-lc

Molecular Characterization of Biotherapeutics The Agilent 1260 Infi nity Multi-Detector Bio-SEC Solution with Advanced Light Scattering Detection

Fast and High Resolution Analysis of Intact and Reduced Therapeutic Monoclonal Antibodies (mabs)

Faster Separations Using Agilent Weak Cation Exchange Columns

Characterization of mab aggregation using a Cary 60 UV-Vis Spectrophotometer and the Agilent 1260 Infinity LC system

Heart-cut 2D-LC/MS approach for pharmaceutical impurity identification using an Agilent 6540 Q-TOF LC/MS System

Qualification of High-Performance Liquid Chromatography Systems

A Comprehensive Workflow to Optimize and Execute Protein Aggregate Studies

Agilent OpenLAB CDS MatchCompare for the Comparison of Peptide Mapping Samples

Application Note. Author. Abstract. Biotherapeutics and Biologics. Sonja Schneider Agilent Technologies, Inc. Waldbronn, Germany

Improving Retention Time Precision and Chromatography of Early Eluting Peptides with Acetonitrile/Water Blends as Solvent B

Application Note. Author. Abstract. Environmental. Edgar Naegele Agilent Technologies, Inc. Waldbronn, Germany

AdvancedTools in HPLC methoddevelopment

Agilent 1290 Infinity II 2D-LC Solution Biopharmaceutical Polymer Analysis. WCBP Jan 2017 Washington, DC

Fast, Low Pressure Analysis of Food and Beverage Additives Using a Superficially Porous Agilent Poroshell 120 EC-C18 Column

Analysis of Intact and C-terminal Digested IgG1 on an Agilent Bio MAb 5 µm Column

Agilent 218 Purification System. Purify your way

Agilent 6430 Triple Quadrupole LC/MS System

NISTmAb characterization with a high-performance RP chromatography column

P. Wadhwani College of Pharmacy, Yavatmal , India. *Corres.author: Cell No

ph gradient analysis of IgG1 therapeutic monoclonal antibodies using a 5 µm WCX column

High-Resolution Charge Variant Analysis for Top-Selling Monoclonal Antibody Therapeutics Using a Linear ph Gradient Separation Platform

Automated fraction re-analysis does it really make sense? Application. Udo Huber. Abstract

A Rapid Method for Trace Analysis of Organophosphorus Pesticides in Drinking Water

Reproducible LC/MS Peptide Separation Using Agilent AdvanceBio Peptide Plus Columns

Rapid UHPLC Analysis of Reduced Monoclonal Antibodies using an Agilent ZORBAX Rapid Resolution High Definition (RRHD) 300SB-C8 Column

Agilent Prep LC Columns for Small Molecules and Biomolecules MAINTAIN RAPID, RELIABLE SEPARATIONS AS YOU SCALE-UP

Preparative Purification of Corticosteroids by HPLC; Scalability and Loadability Using Agilent Prep C18 HPLC Columns Application

PLRP-S Polymeric Reversed-Phase Column for LC/MS Separation of mabs and ADC

Analysis of Monoclonal Antibody (mab) Using Agilent 1290 Infinity LC System Coupled to Agilent 6530 Accurate-Mass Quadrupole Time-of-Flight (Q-TOF)

Journal of Pharmaceutical and Bioanalytical Science

Agilent Max-Light Cartridge Cell Information for G4212A and G4212B DAD

Transcription:

Analysis of amoxicillin and five impurities on the Agilent Infinity LC System LC analysis of impurities down to the.% level with long sub--µm columns, high flow rates and back pressure greater than bar Application Note Drug Development and Pharmaceutical QA/QC Authors A. Koeberlein Frankenthal, Germany A.G. uesgen Agilent Technologies Waldbronn, Germany mau 8 Impurity A Impurity C Impurity B Impurity D Impurtity E.5.5.5.5.5 min Abstract is an antibacterial drug widely used against gram-positive and gram-negative organisms. In pharmaceutical drug discovery and development, it is crucial to analyze impurities due to their potential for toxic effects on humans. and its impurities were analyzed on the Agilent Infinity LC System on a 5 mm. mm column with.8 µm particles. When using a flow rate of ml/min (at 55 bar), the analysis was completed within seven minutes. Under these conditions, impurities down to a level of.% could be detected. The Agilent Infinity LC System is an ideal instrument for impurity analysis in a pharmaceutical quality control laboratory.

Introduction In pharmaceutical drug discovery and development, it is crucial to analyze for impurities due to their potential for toxic effects on humans. An impurity could be the active pharmaceutical substance itself, a minor byproduct from the production process, a secondary substance in a drug isolated from a natural source, a metabolite created in the human body, or a degradation product of the pharmaceutical agent created under storage conditions. Regulatory agencies stipulate that in the final drug, the amount of an impurity is below.% of the main compound. Recently, a number of publications have dealt with the analysis of amoxicillin and its impurities by PLC with UV or MS detection.,, is an antibacterial drug widely used against gram-positive and gram-negative organisms. It can degrade to several different byproducts, as illustrated in the pathways in Figure. is a polar substance, and its separation requires a high amount of water in the mobile phase. In this Application Note, we use a gradient method in combination with UV detection for the determination of amoxicillin and related impurities. Precision of areas and retention times as well as limits of detection (LD) and limits of quantitation (LQ) for the impurities were evaluated. Linearity in the low nanogram range (trace level) was evaluated for impurities. The Agilent Infinity LC System is an ideal instrument for impurity analysis in a pharmaceutical quality control laboratory. Experimental Instrumentation The instrument used in this application is the Agilent Infinity LC System in the following configuration: Gradient Pump, Autosampler, Column ven and Variable Wavelength Detector. Analyzing amoxicillin requires a column that can tolerate % water as a starting condition. The Agilent ZRBAX SB- Aq column, which is compatible with the highest percentages of water in the mobile phase was used for all experiments. The software used was ChemStation, revision B... N N N S C C C N N N S C C C N N S C C C N C N N N C C S C N N N C C S C penicillinoic acid penilloic acid -ydroxy-phenylglyl amoxicillin 5 Diketopiperazine amoxicillin 5 Figure Degradation pathways of amoxicillin.

Chromatographic conditions Sample: diluted in pure water Column: Agilent ZRBAX SB-Aq. mm 5 mm,.8 µm p/n 89975-9 Mobile phase: A: Water phosphate buffer (. mol/l), p=.8 B: ACN Gradient: Time Component A Component B [min] [%] [%] 5 78 7 Flow rate:. ml/ min, max pressure 55 bar Stop time: 7 min Post time: min Detector: VWD 9 nm Peak width: PW >.5 min, z Injection Vol: µl Column temp: C Sample preparation Sample compounds: Level 5 Amount Amount Amount Amount Amount Amount (ng/µl) (ng/µl) (ng/µl) (ng/µl) (ng/µl) (ng/µl) Impurity A.9.5.8.9.5.8 Impurity B.9.8.9.9.8.9 Impurity C.9 5.5.8.9.55.8 Impurity D.57.785.7.57.785.7 Impurity E 5.8..5.58..5 Table Concentratiion levels of impurities. Results and discussion Precision of retention times and areas Precision of areas and retention times was evaluated with concentration level (Figure ). The injection volume was µl. The resolution for impurity B is.97. ther impurities and degradation products are observed in the chromatogram, but in Figure, only the impurities and degradation products shown in Table were determined. Table shows the precision of retention times and areas of amoxicillin impurities. trihydrate Impurity A, p-hydroxy-phenylglycine Impurity B, Penicilloic acid mau 8 Impurity A Impurity C, -Aminopenicillanic acid Impurity D, p-hydroxy-phenylglycyl Impurity E, Diketopiperazine- A stock solution of amoxicillin was prepared in water with a concentration of mg/ml. Solutions for the evaluation of impurity data were prepared in water (Table ). Different concentration levels were used for testing the precision of retention times and areas for the evaluation of LD, LQ and linearity. Impurity C Impurity B.5.5.5.5.5 Figure Concentration level for testing precision of retention times and areas over eight runs, µl injected, maximum pressure of 55 bar at ml/min flow rate. Impurity D Impurtity E min

Impurity A Impurity B Impurity C Impurity D Impurity E Ret Time Ret Time Ret Time Ret Time Ret Time Ret Time n=8 (min) (mau s) (min) (mau s) (min) (mau s) (min) (mau s) (min) (mau s) (min) (mau s) Mean:.88.7..88.8.7...55.87.5 5.75 S.D.:.89E- 9.59E-.E-.5E-.5E- 9.8E-.E-.88E- 7.8E-.E-.E-.8E- RSD:.5.895.7..5.88..9....9 Table Precision of RT and areas of amoxicillin and impurities for level concentration. The precision of retention times is between.% and.% RSD for all peaks. The precision of areas is between.5% and.9% RSD for impurities with area counts between.9 and mau s. Linearity Linearity was tested over all six concentration levels (Figure ). The linearity is better than.999 for the factor of correlation. 8 5 Impurity A, =.5*Amt +.7 Rel. Res%():.59e 7.5 5 7.5 Correlation:.99999.5.5.5 5 Impurity B, =.9*Amt +.7 Rel. Res%(): _.85e- Correlation:.999.5 5 7.5.75.5.5.75.5.5 5 Impurity C, =.77*Amt +.98 Rel. Res%():.99 5 Correlation:.99987.5.5 Impurity D, =.8*Amt +.85 Rel. Res%(): _. 5 Correlation:.99998 5 5 Impurity E, =.757*Amt +.9 Rel. Res%():.7 5 Correlation:.99987 Figure Linearity of impurities over all six concentration levels.

The limit of detection for the impurities was between. ng and.7 ng injected amount with a signal-to-noise ratio of (Figure red trace). Level was used to determine the minimum detectable level. The limit of quantitation was times higher, close to concentration level, (Figure 5 blue trace). mau.8... Impurity A Concentration level (LQ blue) and (LD red) Impurity C Impurity B Impurity D Impurity E In Table, the results for LD and LQ are combined. _..5.5.5.5 Noise range min Figure Concentration level (blue trace) and level (red trace), µl injected. Concentration LQ Concentration LD level (times LD) level amount (ng/µl) amount (ng/µl) amount (ng/µl) amount (ng/µl) Impurity A..8..9 Impurity C.7.9..9 Impurity B..8..9 Impurity D.75.7.5.57 Impurity E.7.5.9.58 Table Results for LD and LQ. 5

Analysis of the amoxicillin sample Figure 5 shows the chromatogram of the amoxicillin sample. The sample was dissolved in water to a final concentration of mg/ml. The results are presented in Table, showing that impurities in the.% range can be detected. is present at a percentage level of 9%. The percentage levels for the impurities are calculated in relation to this level. mau 8 Sample amount: mg/ml test sample Impurity A Impurity C Impurity B Impurity D Impurtity E.5.5.5.5.5 min Figure 5 sample, µl injected. (mau s) ng/µl Percentage Impurity A 8.59..5 Impurity C..87. Impurity B.989 8.79. Impurity D 8.757.777.5 Impurity E.798.7575..9 9 Table Results of real life sample.

Conclusion and its impurities were analyzed on the Agilent Infinity LC System using a 5 mm. mm column with.8 µm particles. At a flow rate of ml/min (at 55 bar) the analysis was completed within seven minutes. Under these conditions, impurities down to a level of.% could be detected. This shows that the Agilent Infinity LC System is an ideal instrument for impurity analysis in a pharmaceutical quality control laboratory. References. Ch.B.V.N.Raju, et al., RP-PLC method for analysis of related substances in Amoxicllin Drug substance, Acta Chromatographia,, 57 7, 9. Edgar Naegele et al., Structure elucidation of degradation products of the antibiotic drug, Agilent Technologies publication 5989-7EN, 5. Edgar Naegele, Statistic evaluation of mass accuracy measurements by ESI TF with a sample of degradation products from the antibiotic drug, Agilent Technologies publication 5989-5EN, 5 7

www.agilent.com/chem/ Agilent Technologies, Inc., July, Publication Number 599-9EN